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proteins, but none has yet found its way into routine patient 
care. Attempts to individualize treatment according to the 
tumor’s somatic mutation profile are novel but so far imprac-
tical.  Conclusions: Progress in the treatment of pancreatic 
cancer has been exceedingly slow and mostly dependent on 
improved pharmaceutical preparations or combinations of 
established chemotherapeutic agents. The promise of major 
breakthroughs implied in targeting tumor signal transduc-
tion events has so far not materialized.  © 2016 S. Karger AG, Basel 
 Introduction 
 Pancreatic cancer is currently the 4th leading cause of 
cancer death and projected to become the 3rd leading 
cause of cancer-related death by 2030 due to delayed di-
agnosis and slow progress in treatment development  [1] . 
The dismal prognosis of pancreatic cancer is caused by a 
variety of factors: (a) due to its location in the retroperito-
neum, pancreatic cancer causes symptoms only when it 
has already grown to an advanced stage and is no longer 
locally resectable  [2] . (b) Pancreatic cancer has a tendency 
to disseminate not only into the bloodstream and into the 
lymphatic tissue but also along nerve fibers, leading to an 
unusually high recurrence rate even after successful R0 
resection  [3] . For both these issues, a current consensus 
predicts that methods allowing earlier detection of pan-
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 Background: Pancreatic ductal adenocarcinoma (PDAC) is 
the 4th leading cause of cancer death worldwide and com-
pared to other malignancies its share in cancer mortality is 
expected to rise further. This is due to a lack of sensitive di-
agnostic tools that would permit earlier detection in a poten-
tially curable stage and the very slow progress in finding ef-
fective drug treatments for pancreatic cancer.  Key Messag-
es: Aside from genetic predispositions and environmental 
agents, chronic pancreatitis is by far the greatest risk factor 
for PDAC. It also shares several etiological factors with pan-
creatic cancer and represents its most challenging differen-
tial diagnosis. Biomarkers that can distinguish between 
chronic pancreatitis and PDAC may therefore be suitable for 
the latter’s early detection. Moreover, targeting the natural 
history of chronic pancreatitis would be one approach to 
prevent PDAC. Targeting tumor-cell signaling directly by in-
terfering with receptor tyrosine kinases has shown some ef-
ficacy, although the results in clinical trials were less encour-
aging than for other cancers. Other compounds developed 
have targeted the formation of extracellular matrix around 
the tumor, the proteolytic activity in the tumor environment, 
histone deacetylases, hedgehog signaling and heat shock 
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creatic cancer would be of benefit and improve survival 
 [4] . (c) Pancreatic cancer is highly resistant to chemother-
apy, radiation therapy and even targeted therapy  [5] .
 Early Detection of Pancreatic Cancer 
 In the context of early detection methods and outside 
of imaging technologies, only very few biomarkers have 
been identified so far that could either distinguish pan-
creatic cancer from other disorders of the pancreas or de-
tect it earlier than with currently available methods. The 
best established blood test for this purpose is carbohy-
drate antigen 19-9 (CA19-9), a Lewis antigen of the 
MUC1 protein-class. Unfortunately, CA19-9 can also be 
elevated in patients with nonmalignant diseases includ-
ing liver cirrhosis, chronic pancreatitis and cholangitis as 
well as other gastrointestinal cancers  [6] . CA19-9 has 
been reported to discriminate between pancreatic cancer 
patients and healthy controls with a sensitivity and spec-
ificity of slightly over 80%  [7] and between pancreatic 
ductal adenocarcinoma (PDAC) and benign pancreatic 
disease with a sensitivity of 78% and a specificity of 83% 
 [8] . However, CA19-9 is not expressed in Lewis blood 
type negative patients and this limits the optimum of any 
test relying on CA19-9 at a sensitivity of 92% under the 
best of circumstances. In up to one third of patients, the 
distinction between chronic pancreatitis and PDAC is in-
accurate and the negative predictive value of diagnostic 
assays is often no better than 50–60%  [1] . This has 
prompted a search for diagnostic biomarkers in blood 
and other body fluids (including saliva) for 2 purposes: to 
distinguish between benign pancreatic disease and pan-
creatic cancer and to detect PDAC earlier than currently 
possible with established imaging techniques. One very 
promising step in this quest is the detection of exosomes 
or microRNA patterns with a reasonable degree of speci-
ficity for PDAC  [9] . Our group has taken a different ap-
proach and searched for metabolic biomarkers using a 
metabolomics approach including lipidomics. In more 
than 900 patients and appropriate controls, we were able 
to identify a distinct biomarker signature that can distin-
guish pancreatic cancer from chronic pancreatitis with 
greater sensitivity and specificity than CA19-9 and would 
improve the accuracy of the detection in 30% of patients 
 [10] . Biomarker signatures (panels of multiple markers), 
rather than single individual parameters appear presently 
the most promising approach to early pancreatic cancer 
detection and thus the diagnosis in a potentially curable 
stage. Whether they can be employed in a population-
based screening approach rather than being used only to 
make the distinction between clinically manifest benign 
and malignant pancreatic disorders has not been estab-
lished and requires further studies.
 Treatments Resistance of Pancreatic Cancer 
 The issue of therapy resistance is even harder to ad-
dress. Some progress has been made over recent decades 
in identifying chemotherapy regimens that increase the 
overall survival of patients with pancreatic cancer. The 
most notable success was to establish that adjuvant che-
motherapy in pancreatic and ampullary cancer can dou-
ble the survival of patients after successful resection of the 
tumor  [11, 12] . However, the fact that this merely repre-
sents an improvement from 10% to approximately 20% 
overall survival after 5 years only highlights the extensive 
treatment resistance and almost limitless recurrence po-
tential of this tumor. For patients in whom surgery is not 
an option because the tumor is locally advanced, usually 
with artery encasement beyond a resectable stage, or be-
cause of metastasis formation, palliative chemotherapy is 
currently the only therapeutic option. Improvements in 
overall survival have been achieved in recent years, albeit 
the extent is limited. One regimen that was found to con-
fer a survival benefit was the combination of several long 
established cytotoxic compounds such as 5FU, irinotecan 
and oxaliplatin  [13] . Another used a new albumin-encap-
sulated preparation of paclitaxel in combination with 
gemcitabine and found it superior to the long-standing 
standard regimen of gemcitabine alone  [14] . A similar ap-
proach to improving the tumor penetrance of established 
chemotherapeutic agents was taken with irinotecan, a li-
posomal preparation of which has resulted in encourag-
ing initial studies  [15] and will probably be approved for 
pancreatic cancer within the next months. These regi-
mens have improved the median overall survival from 
5 months to no more than 11 months and thus represent 
a much lesser treatment advance than achieved for pa-
tients with colorectal cancer or other solid tumors. A 
summary of currently available treatment options can be 
found in  table 1 .
 Potential and Established Treatment Targets 
 A variety of structures have been targeted in pancre-
atic cancer such as the EGF receptor, the VEGF receptor, 
fibroblast activation protein α5β1-Integin, and others 
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without resulting in a significant clinical benefit. Neither 
overexpression of TNFα nor the use of broad spectrum 
receptor tyrosine kinase inhibitors has met the high ex-
pectations of patients and physicians. The only tyrosine 
kinase inhibitor found to confer a survival advantage so 
far was erlotinib, a small molecule originally designed to 
interfere with EGF receptor signaling but probably also 
effective against more than 20 other RTKs  [16] . Not every 
patient benefits from treatment with erlotinib but only 
those who develop a prominent skin rash. The skin rash 
therefore serves as a biomarker sign and can be used to 
determine whether or not a continuation of the treatment 
beyond a few weeks is of any benefit to the patient. Other 
RTKs  [17] are currently under investigation as potential 
treatment targets and it is much hoped that novel com-
pounds directed against them can match or surpass the 
results achieved with erlotinib.
 Since more than 90% of pancreatic cancer specimens 
carry somatic mutations in the proto-oncogene  KRAS 
this has turned into an attractive target. The disadvantage 
of the RAS pathway is that it is vital for cellular survival 
in all tissues and not only cancer cells. This poses a num-
ber of difficulties for developing tumor-specific anti-RAS 
therapies. Other targets that are currently under investi-
gation include polo-like kinase and heat shock protein 70, 
the latter of which appears to be involved in tumor cell 
resistance to apoptosis  [18] . The dissemination of tumor 
cells into neighboring organs depends on the function of 
intact cell–cell adhesions  [2], which impair metastasis 
formation. Histone deacetylases HDAC1 and HDAC2 
are potent regulators of cell-contact protein formation 
and have therefore (including their inhibitors) become a 
much investigated target for pancreatic cancer treatment 
modalities  [19] . The jury is still out as to whether or not 
they are of any benefit to patients. Once the appropriate 
target has been identified, there remains the challenge of 
how to deliver the compound to the tumor cells in a can-
cer that produces abundant extracellular matrix, an often 
severe impediment to drug delivery. To address this chal-
lenge a number of techniques including microspheres 
and the abovementioned albumin- or liposome encapsu-
lation of compounds have been invented. Other strategies 
target the tumor stoma directly.
 Targeting Extracellular Matrix Deposition 
 One of the well-researched explanations why pancre-
atic cancer is so resistant to chemotherapy is the fact that 
it produces extensive extracellular matrix  [20] encapsu-
lating the tumor, a phenomenon it shares with chronic 
pancreatitis  [21] , and that any systemically administered 
medication can simply not reach the tumor across this 
barrier  [22] . This assumption has prompted the develop-
ment of several strategies intended to overcome the ma-
trix barrier and to degrade or digest its components in 
pancreatic cancer  [23] . Recent experimental evidence 
suggests that this may not necessarily be beneficial and 
could even render the exposed tumor cells more aggres-
sive  [24, 25] . Inhibition of the hedgehog pathway, regard-
Table 1.  Life expectancy in patients with pancreatic cancer
5-year overall survival of all patients, % 0.4
5-year overall survival after resection and adjuvant chemotherapy, % 20
Median survival, months
All patients, best supportive care 5
Chemotherapy with gemcitabine 6
Chemotherapy with gemcitabine plus capecitabine 7
Chemotherapy with gemcitabine plus nab-paclitaxel 9
Chemotherapy with gemcitabine plus erlotinib (in case of rash) 10
Chemotherapy with FOLFIRINOX 11
Resection without adjuvant chemotherapy 16
Resection with adjuvant chemotherapy (gemcitabine or 5 fluoruracil) 23
Current average gain in life expectancy by surgery, months 12–17 
Gudjonsson B: Cancer 1987;60:2284–2303 [52] Neoptolemos JP, et al: JAMA 2010;304:1073–1081 [11]
Neoptolemos JP, et al: N Engl J Med 2004;350:1200–1210 [53] Burris HA 3rd, et al: J Clin Oncol 1997;15:2403–2413 [54]
Moore MJ et al: J Clin Oncol 2007;25:1960–1966 [16] Cunningham D, et al: J Clin Oncol 2009;27:5513–5518 [55]
Conroy T, et al: N Engl J Med 2011;364:1817–1825 [13] Goldstein D, et al: J Natl Cancer Inst 2015;pii:dju413 [14]
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ed as crucial for pancreatic cancer desmoplasia and ma-
trix deposition, also resulted in disappointing outcomes 
 [26] . The longstanding discussion of whether the extra-
cellular matrix protects the patient from a dissemination 
of his tumor or whether it protects the tumor from the 
penetration of chemotherapeutic agents or tumor-lytic 
inflammatory cells appears not to be settled for the mo-
ment.
 Precision Therapy 
 Pancreatic cancer is known to carry a multitude of 
somatic mutations affecting a finite number of signal 
transduction pathways. A strategy has therefore been 
developed; it is broadly based on the concept of indi-
vidualized medicine, more recently termed precision 
medicine. The approach involves taking a tumor biopsy, 
analyzing the tumor genome and characterizing the sig-
naling pathways that have undergone pathological al-
terations. Based on these findings, an individually con-
fectioned cocktail of antiproliferative agents or inhibi-
tors of signal transduction pathways shall then be 
administered. Investigators have so far screened for es-
tablished molecular targets such as  HER2 amplification , 
KRAS wild-type, and mutations in DNA damage repair 
pathways ( BRCA1 , BRCA2 , PALB2 , ATM ). The first pi-
lot results are not encouraging but the greatest impedi-
ments are mostly technical. They include the need to 
obtain a sufficient number of tumor cells on biopsy or 
the delay of 3 weeks until final results are translated into 
a therapy, which resulted in an unacceptable dropout 
rate in one study  [27] . However, these difficulties will 
most likely be overcome by technical improvements and 
only then can individualization of therapy according to 
the genomic tumor profile be assessed with a sufficient 
degree of robustness.
 Pancreatic Cancer and Chronic Pancreatitis 
 Chronic pancreatitis is not only the single most sig-
nificant risk factor for the development of pancreatic can-
cer but also an important differential diagnosis  [28] . Par-
ticularly patients suffering from the hereditary variety of 
chronic pancreatitis that is associated with mutations in 
the cationic trypsinogen ( PRSS1 ) gene have a 40–70% 
lifetime risk of developing pancreatic cancer  [29] . They 
further double their cancer risk if additional environmen-
tal factors such as cigarette smoking contribute to this 
condition  [30] . It seems presently unlikely that acute pan-
creatitis  [31] can contribute to the pancreatic cancer risk, 
but for autoimmune pancreatitis, a possible association 
has not been ruled out  [32, 33] .
 Chronic pancreatitis and pancreatic cancer share a 
number of underlying mechanisms and risk factors. 
Common to all forms of pancreatitis is a prominent role 
of trypsin, a digestive protease that is prematurely acti-
vated in the early disease phase  [34, 35] and mutations in 
one of the isoforms of which ( PRSS1 ) confer the greatest 
risk of developing hereditary pancreatitis  [28, 29] , the dis-
ease variety burdened with the greatest risk of developing 
pancreatic cancer  [29, 30] . Interestingly, trypsin is also 
immunogenic and has been implicated in the pathogen-
esis of autoimmune pancreatitis  [36] . The role of trypsin 
in pancreatic cancer is less clear, but several studies have 
implicated this digestive protease as either a biomarker 
 [37] or a pathogenetic factor  [38] for adenocarcinoma of 
the pancreas. The same connection applies to another 
group of proteases, lysosomal cathepsins, secreted by the 
exocrine pancreas in significant quantities  [39, 40] , play 
a prominent role in the activation of trypsin during pan-
creatitis  [41, 42] , but have also been identified in pancre-
atic cancer tissue, where their presence appears to be a 
biomarker for a poor prognosis  [43] . Their pathogenetic 
role in cancer is assumed to require an involvement in the 
interaction between cancer cells and extracellular matrix.
 Another common mechanism between pancreatitis 
and cancer deals with the functional impairment of cell–
cell contacts  [44] , which not only permits the transloca-
tion of inflammatory cells into the pancreas  [45, 46] , but 
at the same time allows for the dissemination of malig-
nant cells from the tumor to peripheral organs  [2] . Among 
the cell contact, protein families that have been shown to 
be involved in tumor development are claudins  [47] , mu-
tations in which have recently been reported to also rep-
resent a risk factor for chronic pancreatitis  [48] .
 The last factor on this incomplete list worth mention-
ing, and presently the most puzzling, is the ABO blood 
type. Blood types are a surrogate for the degree to which 
certain cellular proteins, and not only those on red blood 
cells, undergo surface glycosylation. It has been shown 
that the blood type B not only increases the lifetime risk 
of developing pancreatic cancer  [49] , but also doubles the 
risk of developing chronic pancreatitis  [50] . Whether or 
not the underlying mechanisms indicated by blood type 
B only signals an unspecific cellular stress (ER-stress) re-
sponse as common denominator for pancreatitis and 
cancer or rather points to a distinct set of proteins that 
need to undergo specific glycosylation events for the dis-
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ease risk to materialize is presently unknown. Studies that 
attempt to solve this question are ongoing.
 At present it appears plausible that any target that is 
common to pancreatitis and pancreatic cancer has the 
greatest potential for leading to a preventive strategy. As 
shown for other inflammatory disorders such as ulcer-
ative colitis and hepatitis, it is likely that approaches with 
a beneficial effect on the natural disease course of pan-
creatitis will have an impact on the development of pan-
creatic cancer. Currently there is none, and therapy for 
chronic pancreatitis remains strictly symptomatic or 
complication oriented. This needs to change before 
greater progress in the management of patients with pan-
creatitis and in the prevention of pancreatic cancer can 
be expected [51]. Pancreatic cancer surgery is, in all but 
a tiny minority of patients, as much a palliative approach 
as conventional chemotherapy. It is at present just the 
better palliation and prolongs the patients live signifi-
cantly longer. For medical therapy of pancreatic cancer 
to be more successful, two issues need to be resolved: (a) 
how to target tumor cells or tumor stem cells more spe-
cifically, effectively and sustainably and (b) how to de-
liver this therapy to a tumor across a highly impenetrable 
extracellular matrix barrier. A large-scale concerted ef-
fort by the research community and its funding agencies 
is required to make this deadly disease not only a non-
surgical disorder but also a curable condition.
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